This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Trigger factors in ANCA associated vasculitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • the predominance of respiratory involvement, especially in GPA (Wegener's), led to investigation of the role of inhaled agents in the development of GPA

  • they observed no increase in inhaled particulates and fumes in GPA in general, but a significant increase in those with respiratory disease

  • a number of other possible trigger factors have also been reported, including silica, solvents, allergy and vaccination. A number of drugs have been implicated in the development of ANCA associated vasculitis (AAV)

  • patients with high-titre MPO antibodies are more likely to have taken hydralazine, propylthiouracil or allopurinol

  • leucotriene antagonists have been associated with development of EGPA (Churg Strauss), probably by unmasking pre-existing disease

Reference:

  • 1) ARC Autumn 2012. Topical Reviews - ANCA-associated vasculitis; 1:1-12.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.